4.7 Article

Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial

Journal

EBIOMEDICINE
Volume 24, Issue -, Pages 159-165

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2017.09.013

Keywords

Probiotic; Depression; Anxiety; Randomised controlled trial; Microbiome-gut-brain axis

Funding

  1. Health Research Council of New Zealand [HRC 11/318]
  2. Fonterra Co-operative Group Ltd., New Zealand
  3. University of Otago, Wellington, New Zealand
  4. Fonterra
  5. Cure Kids

Ask authors/readers for more resources

Background: Probiotics may help to prevent symptoms of anxiety and depression through several putative mechanisms. Objective: The aim of this study was to evaluate the effect of Lactobacillus rhamnosus HN001 (HN001) given in pregnancy and postpartum on symptoms of maternal depression and anxiety in the postpartum period. This was a secondary outcome, the primary outcome being eczema in the offspring at 12 months of age. Design, Setting, Participants: A randomised, double-blind, placebo-controlled trial of the effect of HN001 on postnatal mood was conducted in 423 women in Auckland and Wellington, New Zealand. Women were recruited at 14-16 weeks gestation. Intervention: Women were randomised to receive either placebo or HN001 daily fromenrolment until 6 months postpartum if breastfeeding. Outcome Measures: Modified versions of the Edinburgh Postnatal Depression Scale and State Trait Anxiety Inventory were used to assess symptoms of depression and anxiety postpartum. Trial Registration: Australia NZ Clinical Trials Registry: ACTRN12612000196842. Findings: 423 womenwere recruited between December 2012 and November 2014. 212 womenwere randomised to HN001 and 211 to placebo. 380 women (89.8%) completed the questionnaire on psychological outcomes, 193 (91.0%) in the treatment group and 187 (88.6%) in the placebo group. Mothers in the probiotic treatment group reported significantly lower depression scores (HN001 mean= 7.7 (SD = 5.4), placebo 9.0 (6.0); effect size-1.2, (95% CI-2.3,-0.1), p= 0.037) and anxiety scores (HN001 12.0 (4.0), placebo 13.0 (4.0); effect size-1.0 (-1.9, -0.2), p = 0.014) than those in the placebo group. Rates of clinically relevant anxiety on screening (score N 15) were significantly lower in the HN001 treated mothers (OR = 0.44 (0.26, 0.73), p = 0.002). Interpretation: Women who received HN001 had significantly lower depression and anxiety scores in the postpartum period. This probioticmay be useful for the prevention or treatment of symptoms of depression and anxiety postpartum. (C) 2017 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available